01降糖新方案瑞乐唐是由钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)、二肽基肽酶-4抑制剂(DPP-4i)和二甲双胍组成的三药联合固定复方制剂。具体来看,其三大组分各具特色、协同增效:脯氨酸恒格列净作为我国首个自主研发的SGLT2i,通过抑制肾脏肾小管对葡萄糖的重吸收,促使多余糖分随尿液排出,从而实现直接降糖。该药物不依赖胰岛素机制,兼具减轻体重、降压及心血管保护等多重获益;磷酸瑞格列汀是国内首个...
Source Link01降糖新方案瑞乐唐是由钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)、二肽基肽酶-4抑制剂(DPP-4i)和二甲双胍组成的三药联合固定复方制剂。具体来看,其三大组分各具特色、协同增效:脯氨酸恒格列净作为我国首个自主研发的SGLT2i,通过抑制肾脏肾小管对葡萄糖的重吸收,促使多余糖分随尿液排出,从而实现直接降糖。该药物不依赖胰岛素机制,兼具减轻体重、降压及心血管保护等多重获益;磷酸瑞格列汀是国内首个...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.